Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia.
Babushok DV, DeZern AE, de Castro C, Rogers ZR, Beenhouwer D, Broder MS, Fanning S, Gibbs SN, Hanna R, Maciejewski JP, Scott BL, Tantravahi SK, Wlodarski MW, Yermilov I, Patel BJ. Babushok DV, et al. Among authors: dezern ae. Blood Adv. 2024 Apr 26:bloodadvances.2023011642. doi: 10.1182/bloodadvances.2023011642. Online ahead of print. Blood Adv. 2024. PMID: 38669341
Myelodysplastic syndromes, version 2.2015.
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network. Greenberg PL, et al. Among authors: dezern ae. J Natl Compr Canc Netw. 2015 Mar;13(3):261-72. doi: 10.6004/jnccn.2015.0038. J Natl Compr Canc Netw. 2015. PMID: 25736003 Free PMC article.
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Zeidan AM, et al. Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173. Am J Hematol. 2015. PMID: 26284571 Free article.
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium. Nazha A, et al. Among authors: dezern ae. Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22. Leuk Res. 2016. PMID: 26777537 Free PMC article.
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. Montalban-Bravo G, et al. Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989. Blood Adv. 2019. PMID: 30902805 Free PMC article.
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.
Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Nazha A, et al. JCO Precis Oncol. 2019;3:PO.19.00119. doi: 10.1200/po.19.00119. Epub 2019 Sep 20. JCO Precis Oncol. 2019. PMID: 31663066 Free PMC article.
Stem cell donors should be screened for CHIP.
DeZern AE, Gondek LP. DeZern AE, et al. Blood Adv. 2020 Feb 25;4(4):784-788. doi: 10.1182/bloodadvances.2019000394. Blood Adv. 2020. PMID: 32097458 Free PMC article.
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Sallman DA, et al. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e597-e605. doi: 10.1016/j.clml.2020.03.005. Epub 2020 Mar 20. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32303488
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston N, Ambinder RF, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA. DeZern AE, et al. Blood Adv. 2020 Apr 28;4(8):1770-1779. doi: 10.1182/bloodadvances.2020001729. Blood Adv. 2020. PMID: 32343796 Free PMC article.
184 results